Liquidia (NASDAQ:LQDA) General Counsel Sells $34,507.68 in Stock

Liquidia Corporation (NASDAQ:LQDA) General Counsel Russell Schundler sold 1,072 shares of the company’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $32.19, for a total transaction of $34,507.68. Following the completion of the transaction, the general counsel owned 577,288 shares of the company’s stock, valued at $18,582,900.72. This trade represents a 0.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Russell Schundler also recently made the following trade(s):

• On Monday, October 13th, Russell Schundler sold 7,839 shares of Liquidia stock. The stock was sold at an average price of $23.41, for a total transaction of $183,510.99.

Liquidia Stock Performance

Liquidia stock opened at $33.92 on Friday. Liquidia Corporation has a fifty-two week low of $10.37 and a fifty-two week high of $34.08. The stock’s 50 day simple moving average is $26.04 and its two-hundred day simple moving average is $21.73. The company has a debt-to-equity ratio of 6.19, a quick ratio of 1.96 and a current ratio of 2.20. The stock has a market cap of $2.95 billion, a price-to-earnings ratio of -23.56 and a beta of 0.48.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Monday, November 3rd. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.41. The firm had revenue of $54.34 million during the quarter, compared to analyst estimates of $18.86 million. Liquidia had a negative return on equity of 296.78% and a negative net margin of 176.04%.The company’s quarterly revenue was up 1106.7% compared to the same quarter last year. As a group, analysts expect that Liquidia Corporation will post -1.51 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Cetera Investment Advisers increased its holdings in Liquidia by 34.4% in the 1st quarter. Cetera Investment Advisers now owns 41,999 shares of the company’s stock worth $619,000 after buying an additional 10,756 shares in the last quarter. CenterBook Partners LP purchased a new stake in shares of Liquidia during the 1st quarter valued at about $1,786,000. Aigen Investment Management LP purchased a new stake in shares of Liquidia during the 1st quarter valued at about $151,000. Nuveen LLC bought a new stake in shares of Liquidia in the first quarter worth approximately $2,642,000. Finally, Kovitz Investment Group Partners LLC bought a new stake in shares of Liquidia in the first quarter worth approximately $384,000. 64.54% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have weighed in on LQDA. Wells Fargo & Company began coverage on shares of Liquidia in a report on Monday, October 20th. They issued an “overweight” rating and a $31.00 price objective on the stock. Raymond James Financial reissued a “strong-buy” rating and issued a $47.00 price target on shares of Liquidia in a research report on Tuesday, November 4th. BTIG Research reaffirmed a “buy” rating and set a $49.00 price objective on shares of Liquidia in a research report on Tuesday, November 4th. HC Wainwright increased their target price on Liquidia from $35.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Finally, Jefferies Financial Group restated a “buy” rating and set a $45.00 price target on shares of Liquidia in a report on Monday, November 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Liquidia presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.56.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).